Regulation of mesenchymal stem cell differentiation on microstructured titanium surfaces by semaphorin 3A.
Implant
Mesenchymal stem cell
Osteoblast
Semaphorin3A
Surface topography
Titanium
Journal
Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
03
10
2019
revised:
30
01
2020
accepted:
01
02
2020
pubmed:
7
2
2020
medline:
18
5
2021
entrez:
7
2
2020
Statut:
ppublish
Résumé
Peri-implant bone formation depends on the ability of mesenchymal stem cells (MSCs) to colonize implant surfaces and differentiate into osteoblasts, but the precise mechanisms controlling this process remain unclear. In vitro, MSCs undergo osteoblastic differentiation on microstructured titanium (Ti) surfaces in the absence of exogenous media supplements and produce factors that promote osteogenesis while regulating osteoclast activity, including semaphorins. The goal of this study was to evaluate the role of semaphorin 3A (Sema3A) on surface-mediated osteoblastic differentiation and determine the hierarchy of this signaling cascade. Human MSCs were cultured on 15 mm grade 2 smooth (pretreatment, PT), hydrophobic-microrough (sand blasted/acid etched, SLA), hydrophilic-microrough Ti (mSLA) (Institut Straumann AG, Basel, Switzerland), or tissue culture polystyrene (TCPS). Expression of SEMA3A family proteins increased after 7 days of culture, and the increased expression in response to microstructured Ti was dependent on recognition of the surface by integrin α2β1. Exogenous Sema3A increased differentiation whereas differentiation was decreased in cells treated with a Sema3A antibody. Furthermore, Sema3A influenced the production of osteoprotegerin and osteopontin suggesting it as an important local regulator of bone remodeling. Inhibition of Wnt3A and Wnt5A revealed that activation of Sema3A occurs downstream of Wnt5A and may facilitate the translocation of β-catenin bypassing the canonical Wnt3A initiating signal associated with osteoblastic differentiation. Furthermore, chemical inhibition of calmodulin (CaM), Ca
Identifiants
pubmed: 32028017
pii: S8756-3282(20)30040-5
doi: 10.1016/j.bone.2020.115260
pmc: PMC7749709
mid: NIHMS1563641
pii:
doi:
Substances chimiques
Semaphorin-3A
0
Titanium
D1JT611TNE
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
115260Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR052102
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR072500
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Semin Cell Dev Biol. 2013 Mar;24(3):163-71
pubmed: 23022498
Mol Cell Endocrinol. 2016 Sep 5;432:66-74
pubmed: 26365296
Acta Biomater. 2011 Jun;7(6):2740-50
pubmed: 21352958
Nat Rev Immunol. 2013 Nov;13(11):802-14
pubmed: 24319778
J Periodontol. 1999 Dec;70(12):1523-39
pubmed: 10632528
Int J Dev Biol. 2011;55(4-5):439-45
pubmed: 21858769
Nat Cell Biol. 2006 Jun;8(6):615-22
pubmed: 16715077
Cell Mol Life Sci. 2019 Apr;76(7):1243-1253
pubmed: 30515522
Calcif Tissue Int. 2012 Feb;90(2):151-62
pubmed: 22227882
Mol Biol Cell. 2000 Mar;11(3):1023-35
pubmed: 10712517
Biochim Biophys Acta. 2014 Nov;1843(11):2365-75
pubmed: 24946135
Nature. 2007 Apr 5;446(7136):680-4
pubmed: 17377534
Clin Biochem. 2012 Aug;45(12):863-73
pubmed: 22465238
Curr Opin Neurobiol. 2002 Oct;12(5):532-41
pubmed: 12367632
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1584-93
pubmed: 25973043
J Bone Miner Res. 1992 Aug;7(8):877-85
pubmed: 1442202
Proc Natl Acad Sci U S A. 1990 Jun;87(12):4473-5
pubmed: 1693772
J Cell Biochem. 1991 Mar;45(3):292-302
pubmed: 2066381
J Biomed Mater Res A. 2015 Feb;103(2):564-73
pubmed: 24733736
Cell Mol Immunol. 2010 Mar;7(2):83-8
pubmed: 20118971
Biomaterials. 2009 Jul;30(20):3390-6
pubmed: 19395022
J Biomed Mater Res A. 2016 Dec;104(12):3137-3148
pubmed: 27474858
Nature. 2012 May 3;485(7396):69-74
pubmed: 22522930
Nature. 2013 May 23;497(7450):490-3
pubmed: 23644455
J Endocrinol. 2011 Nov;211(2):131-43
pubmed: 21903860
Sci Rep. 2018 Jun 5;8(1):8588
pubmed: 29872092
Acta Biomater. 2014 Jul;10(7):2907-18
pubmed: 24709541
Bone. 2015 Apr;73:208-16
pubmed: 25554602
Cell Adh Migr. 2014;8(1):5-10
pubmed: 24589620
J Biomed Mater Res A. 2007 Mar 1;80(3):700-10
pubmed: 17133443
JBMR Plus. 2019 Mar 06;3(7):e10184
pubmed: 31372590
Biomaterials. 2006 Jul;27(20):3716-25
pubmed: 16569430
Prostate. 2015 Mar 1;75(4):370-80
pubmed: 25421946
Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75
pubmed: 15928710
Nat Rev Mol Cell Biol. 2005 Oct;6(10):789-800
pubmed: 16314868
Front Cell Neurosci. 2017 Feb 28;11:40
pubmed: 28293171
Acta Biomater. 2014 Aug;10(8):3363-71
pubmed: 24721613
Cell Metab. 2015 Feb 3;21(2):163-173
pubmed: 25651171
Biomaterials. 2012 Oct;33(30):7386-93
pubmed: 22835642
Acta Physiol (Oxf). 2012 Jan;204(1):17-33
pubmed: 21518267
Biochem Biophys Res Commun. 2005 Mar 18;328(3):651-7
pubmed: 15694398
Biomaterials. 2011 Sep;32(27):6399-411
pubmed: 21636130
Biol Cell. 2005 Jul;97(7):589-97
pubmed: 15859945
Acta Biomater. 2016 Feb;31:425-434
pubmed: 26675126
Nat Immunol. 2008 Jan;9(1):17-23
pubmed: 18087252
Clin Oral Implants Res. 2017 Jul;28(7):e51-e59
pubmed: 27273082
Dev Dyn. 2005 Oct;234(2):393-403
pubmed: 16145665
Biomaterials. 2015 May;51:69-79
pubmed: 25770999
Arthritis Res Ther. 2017 Jan 21;19(1):10
pubmed: 28109308
Curr Osteoporos Rep. 2007 Sep;5(3):98-104
pubmed: 17925190
Development. 2014 Sep;141(17):3292-7
pubmed: 25139851
Tissue Eng Part A. 2017 Dec;23(23-24):1479-1489
pubmed: 28793839
Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15767-72
pubmed: 18843104
Biomaterials. 2010 Apr;31(10):2728-35
pubmed: 20053436